

CURRICULUM VITAE**ROCCO PASTANO, MD**

Name	Rocco Pastano
Date of birth	April 28 th , 1966
Nationality	Italian
Phone	+393493700103
E-mail	rocco.pastano@ieo.it
Actual Position	Director-Hematopoietic Stem Cell Transplant Program Division of Hematoncology European Institute of Oncology, IRCCS Via Ripamonti 435 – 20141 Milan

Major career achievement

06/06/2014-06/09/2014	Acting Director Division of Hematoncology European Institute of Oncology
06/06/2014 - present	Director- Hematopoietic Stem Cell Transplant Program Division of Hematoncology European Institute of Oncology
2006 - present	Responsible for JACIE (Joint Accreditation Committee ISCT-Europe & EBMT) accreditation of the Stem Cell Transplant Unit Division of Hematoncology European Institute of Oncology
2003-present	Principal Investigator and co-investigator in several clinical trials mainly focused on allogeneic stem cell transplant Division of Hematoncology European Institute of Oncology
2003-present	Continuing collaboration and sharing of clinical protocols with the Department of Biology of Bone Marrow Transplantation directed by Prof Rainer Storb – Fred Hutchinson Cancer Research Center - Seattle, WA, USA
2002-2004	Startup of the Allogeneic Stem Cell Transplant Unit Division of Hematoncology European Institute of Oncology

Education

05/03/2012	Managerial Qualification for Directors of Complex Unit Regione Lombardia, Milan, Italy
01/04/2011	A 6-Day Managerial Training for Hematologist Scuola di Direzione Aziendale Bocconi University, Milan, Italy
13/11/1999	Specialization in Hematology, Università degli Studi di Bologna, School of Medicine, Bologna, Italy. Score 70/70 cum laude Thesis Title: "Chemotherapy resistance and use of revertant in the therapy of acute myeloid leukemia"
1993	State Board Examination for Medical Licensing in Italy and European Community, Università degli Studi di Bologna, Bologna, Italy

12/07/1993	M.D. Degree, Università degli Studi di Bologna, School of Medicine, Bologna, Italy. Score 110/110 cum laude
06/1990	High School Diploma at Liceo Dante Alighieri, Matera, Italy

Working Experience	
06/06/2014 – present	European Institute of Oncology Milan, Italy
Qualification	Director-Hematopoietic Stem Cell Transplant Program
Main duties and responsibilities	Responsible for the entire Hematopoietic Stem Cell Transplant Program of the Division. Directs the clinical and research activity also ensuring the continuing accreditation of the Program to JACIE, EBMT (European Society for Blood and Marrow Transplantation) and GITMO (Gruppo Italiano Trapianto Midollo Osseo).
06/06/2014-06/09/2014	Division of Hematoncology, European Institute of Oncology Milan, Italy
Qualification	Acting Director – Division of Hematoncology
Main duties and responsibilities	Clinical, managerial, organizational and budget responsibility of the entire Division (12 physicians, 20 inpatient ward and management of a 6 million Euro budget in revenues)
01/07/2010 – present	Division of Hematoncology, European Institute of Oncology Milan, Italy
Qualification	Director-Allogeneic Transplant Unit
Main duties and responsibilities	Clinical responsibility of the patients undergoing allogeneic stem cell transplant. Special focus on designing and advancing clinical trials evaluating new conditioning regimens and the role of haploidentical transplant in hematological malignancies. Managerial responsibility on the junior physicians in the program.
01/04/2007 – 30/06/2010	Division of Hematoncology, European Institute of Oncology Milan, Italy
Qualification	Senior Deputy Director
Main duties and responsibilities	Clinical responsibility of the patients affected by hematological malignancies, focusing of patients undergoing allogeneic stem cell transplant. Responsible for coordinating and organizing the inpatient department and for the management of junior physicians. Principal Investigator and co-investigator of different clinical trials testing new conditioning regimens in patients with haematological malignancies.

<p>01/04/2004 – 31/03/2007</p> <p>Qualification</p> <p>Main duties and responsibilities</p>	<p>Division of Hematoncology, European Institute of Oncology Milan, Italy</p> <p>Senior attending physician</p> <p>Responsible of creating and advancing the Allogeneic Transplant Unit within the Haematology Division. After the establishment of the Unit, actively involved in leading the successful JACIE accreditation of the Unit. Responsible of designing and executing clinical trials of allogeneic stem cell transplantation in haematological malignancies and solid tumours</p>
<p>01/07/2002 – 31/12/2002</p> <p>Qualification</p> <p>Main duties and responsibilities</p>	<p>Fred Hutchinson Cancer Research Center - University of Washington Seattle, WA, USA</p> <p>Visiting Physician</p> <p>Responsible for patients undergoing allogeneic stem cell transplantation, focusing on clinical management of acute and chronic GVHD of more than one thousand patients in different settings: myeloablative and non-myeloablative, HLA identical sibling, matched or mismatched unrelated donor or haploidentical. Clinical management of patients undergoing experimental therapy such anti-CD3 for acute steroid-refractory GVHD or tumour specific CD8 selected DLI for acute leukaemia patients relapsed after transplant.</p>
<p>13/01/2002 – 30/06/2002</p> <p>Qualification</p> <p>Main duties and responsibilities</p>	<p>Laboratory of the Transplant Biology Department Fred Hutchinson Cancer Research Center Seattle, WA, USA</p> <p>Post-doctoral fellow</p> <p>Biologic and clinical evaluation of mixed chimerism. In patients undergoing allogeneic stem cell transplant.</p>
<p>01/01/2001 – 31/03/2004</p> <p>Qualification</p> <p>Main duties and responsibilities</p>	<p>Division of Hematoncology, European Institute of Oncology Milan, Italy</p> <p>Attending Physician</p> <p>Clinical responsibility of patients affected by haematological malignancies with special focus on acute leukemias and on patients undergoing peripheral stem cell mobilization and collection and autologous stem cell transplantation.</p>
<p>01/12/1999 – 31/12/2000</p> <p>Qualification</p> <p>Main duties and responsibilities</p>	<p>Division of Hematoncology, European Institute of Oncology Milan, Italy</p> <p>Fellowship</p> <p>Clinical responsibility of patients affected by haematological malignancies.</p>

Personal Skills

Mother tongue | Italian

Other Language(s) | English

Reading | Excellent
Writing | Excellent
Spoken | Excellent

Communication skills | Great communication and organisational skills

Organisational and
Management Competencies | Excellent Analysis skills
Team working/leading
People management
Problem solving
Objective work propension
Fast learning

Informatics Competencies | Microsoft and Office

Attachments

Clinical trials
Publications

Additional Information

I hereby authorize the use of my personal data according to Italian law 196/2003

Clinical trials

Principal investigator in the following clinical trials:

1. 2003 Non-myeloablative peripheral blood allogeneic stem cell transplant from HLA identical sibling, following conditioning with Fludarabine and low-dose TBI and different immunosuppression tapering on the base of relapse risk in patients with acute and chronic myelo and lympho proliferative disease.
2. 2009 Allogeneic Hematopoietic stem cell transplantation using a Non- Myeloablative preparative regimen of total lymphoid irradiation and anti-Thymocyte globulin for patients with refractory "triple negative" breast cancer
3. 2010 Nonmyeloablative hematopoietic stem cell transplantation for patients with high-risk Hematologic malignancies using related, HLA-haploidentical donors: a Phase II trial of combined immunosuppression with cyclophosphamide administered before and after transplantation.
4. 2010 A monocentric study. IgG antibodies against human Cytomegalovirus late protein UL94 in the pathogenesis of scleroderma-like skin lesions in chronic Graft versus Host Disease.
5. 2012 Nonmyeloablative Hematopoietic Stem Cell Transplantation for patients with solid tumors metastatic or relapsed, resistant/refractory to conventional therapy, using HLA-identical related donors or HLA-Haploidentical related donors: a single centre phase II Trial.

Co-investigator in the following clinical trials:

1. Preliminary study in the evaluation of levels of mature and immature circulating endothelial cells in correlation with presence/absence of acute or chronic GVHD
2. Clinical Phase II trial to evaluate the safety and efficacy of Treosulfan based conditioning prior to allogeneic haematopoietic stem cell transplantation in patients with haematological malignancies.
3. Allogeneic Hematopoietic stem cell transplantation using a Non-Myeloablative preparative regimen of total lymphoid irradiation and anti-Thymocyte globulin for patients with hematologic malignancies.

Publications

Girmeria C, Bertaina A, Piciocchi A, Perruccio K, Algarotti A, Busca A, Cattaneo C, Raiola AM, Guidi S, Iori AP, Candoni A, Irrera G, Milone G, Marcacci G, Scimè R, Musso M, Cudillo L, Sica S, Castagna L, Corradini P, Marchesi F, Pastore D, Alessandrino EP, Annaloro C, Ciceri F, Santarone S, Nassi L, Farina C, Viscoli C, Rossolini GM, Bonifazi F, Rambaldi A; Gruppo Italiano Trapianto di Midollo Osseo (GITMO) and Associazione Microbiologi Clinici Italiani (AMCLI). Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey. *Clin Infect Dis*. 2017 Nov 13;65(11):1884-1896.

Petrella F, Spaggiari L, Acocella F, Barberis M, Bellomi M, Brizzola S, Donghi S, Giardina G, Giordano R, Guarize J, Lazzari L, Montemurro T, **Pastano R**, Rizzo S, Toffalorio F, Tosoni A, Zanotti M. Airway fistula closure after stem-cell infusion. *N Engl J Med*. 2015 Jan 1;372(1):96-7.

Pastano R, Dell'Agnola C, Bason C, Gigli F, Rabascio C, Puccetti A, Tinazzi E, Cetto G, Peccatori F, Martinelli G, Lunardi C. Antibodies against human cytomegalovirus late protein UL94 in the pathogenesis of scleroderma-like skin lesions in chronic graft-versus-host disease. *Int Immunol*. 2012 Sep;24(9):583-91.

Messina G, Giaccone L, Festuccia M, Irrera G, Scortechini I, Sorasio R, Gigli F, Passera R, Cavattoni I, Filippi AR, Schianca FC, Pini M, Risitano AM, Selleri C, Levis A, Mordini N, Gallamini A, **Pastano R**, Casini M, Aglietta M, Montanari M, Console G, Boccadoro M, Ricardi U, Bruno B; Gruppo Italiano Trapianti di Midollo. Multicenter experience using total lymphoid irradiation and antithymocyte globulin as conditioning for allografting in hematological malignancies. *Biol Blood Marrow Transplant*. 2012 Oct;18(10):1600-7.

Martinelli G, Cocorocchio E, Peccatori F, Zucca E, Saletti PC, Calabrese L, **Pastano R**, Pruner G, Mazzetta C, Ghielmini M, Cavalli F. CHIVPP/ABVVP, a first line 'hybrid' combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis. *Br J Haematol*. 2004 Jun;125(5):584-9.

Martinelli G, Laszlo D, Bertolini F, **Pastano R**, Mancuso P, Calleri A, Vanazzi A, Santoro P, Cavalli F, Zucca E. Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma. *Br J Haematol*. 2003 Oct; 123(2):271-7

Chemotherapy of secondary leukemias. Visani G, Pagano L, Pulsoni A, Tosi P, Piccaluga PP, **Pastano R**, Grafone T, Malagola M, Isidori A, Tura S. *Leuk Lymphoma*. 2000 May;37(5-6):543-9. Review.

Visani G, Gugliotta L, Tosi P, Catani L, Vianelli N, Martinelli G, Ottaviani E, Testoni N, Nocentini F, **Pastano R**, Piccaluga P, Isidori A, Grafone T, Tura S. All-trans retinoic acid significantly reduces the incidence of early hemorrhagic death during induction therapy of acute promyelocytic leukemia. *Eur J Haematol*. 2000 Mar;64(3):139-44.

Martinelli G, Ottaviani E, Testoni N, Montefusco V, **Pastano R**, Tura S. Long-term disease-free acute myeloblastic leukemia with inv(16) is associated with PCR undetectable CBFbeta/MYH11 transcript. *Haematologica*. 2000 May; 85(5):552-5.

Alpha-interferon improves survival and remission duration in P-190BCR-ABL positive adult acute lymphoblastic leukemia. Visani G, Martinelli G, Piccaluga P, Tosi P, Amabile M, **Pastano R**, Cavo M, Isidori A, Tura S. *Leukemia*. 2000 Jan;14(1):22-7.

Visani G, Lemoli R, Tosi P, Martinelli G, Testoni N, Ricci P, Motta M, Gherlinzoni F, Leopardi G, **Pastano R**, Rizzi S, Piccaluga P, Isidori A, Tura S. Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells. *Bone Marrow Transplant*. 1999 Sep;24(5):467-72

Testoni N, Borsaru G, Martinelli G, Carboni C, Ruggeri D, Ottaviani E, Pelliconi S, Ricci P, **Pastano R**, Visani G, Zaccaria A, Tura S. 3q21 and 3q26 cytogenetic abnormalities in acute myeloblastic leukemia: biological and clinical features. *Haematologica*. 1999 Aug;84(8):690-4.

Visani G, Lemoli RM, Tosi P, Martinelli G, Testoni N, Ricci P, Piccaluga PP, **Pastano R**, Leopardi G, Dizdari A, Motta MR, Rizzi S, Tura S. Fludarabine-containing regimens severely impair peripheral blood

stem cells mobilization and collection in acute myeloid leukaemia patients. *Br J Haematol.* 1999 Jun;105(3):775-9.

Visani G, Tosi P, Ottaviani E, Zaccaria A, Baccini C, Manfroi S, **Pastano R**, Remiddi C, Morelli A, Molinari AL, Zanchini R, Tura S. All-trans retinoic acid and in vitro cytokine production by acute promyelocytic leukemia cells. *Eur J Haematol.* 1996 Oct;57(4):301-6

Giovannini M, Strippoli P, Serra M, Sironi M, Fincato G, Colotta F, Bonafe M, Biunno I, Mantovani A, Orlandini S, Brandi M, **Pastano R**, Bagnara G. Production of interleukin-6 by human osteoclast-like cells from giant cell tumor of bone. *Int J Oncol.* 1996 Feb; 8(2):297-303.

Essential thrombocythemia: in vitro study of megakaryocytopoiesis

Bagnara GP, Vitale L, Zauli G, Valvassori L, Bonsi L, Strippoli P, **Pastano R**, Catani L, Gugliotta L, Tura S. *Haematologica.* 1991 Jun; 76 Suppl 3:358-60. Italian.